Acceleron Pharma Inc. (NASDAQ:XLRN) had its target price lifted by investment analysts at Barclays PLC from $42.00 to $50.00 in a research report issued on Wednesday. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays PLC’s price target indicates a potential upside of 43.55% from the stock’s current price.

Other analysts have also recently issued reports about the stock. BidaskClub upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Instinet restated a “buy” rating and set a $58.00 price objective on shares of Acceleron Pharma in a research note on Wednesday, June 14th. FBR & Co set a $63.00 price objective on shares of Acceleron Pharma and gave the company a “buy” rating in a research note on Tuesday, June 13th. Oppenheimer Holdings, Inc. set a $40.00 price objective on shares of Acceleron Pharma and gave the company a “buy” rating in a research note on Thursday, June 1st. Finally, Cann restated a “buy” rating and set a $40.00 price objective on shares of Acceleron Pharma in a research note on Thursday, June 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Acceleron Pharma has an average rating of “Buy” and a consensus price target of $42.81.

Shares of Acceleron Pharma (XLRN) traded down 0.63% during mid-day trading on Wednesday, reaching $34.83. 961,324 shares of the company’s stock were exchanged. Acceleron Pharma has a one year low of $23.07 and a one year high of $41.69. The company’s 50-day moving average price is $36.11 and its 200-day moving average price is $31.05. The company’s market capitalization is $1.35 billion.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. The business had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.69 million. During the same quarter in the previous year, the firm posted ($0.59) earnings per share. The business’s revenue was down 3.1% on a year-over-year basis. On average, equities analysts expect that Acceleron Pharma will post ($2.71) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Acceleron Pharma Inc. (XLRN) PT Raised to $50.00 at Barclays PLC” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/23/acceleron-pharma-inc-xlrn-pt-raised-to-50-00-at-barclays-plc.html.

In related news, CFO Kevin F. Mclaughlin sold 34,400 shares of the business’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $32.00, for a total value of $1,100,800.00. Following the completion of the sale, the chief financial officer now owns 80,950 shares of the company’s stock, valued at approximately $2,590,400. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Christopher Rovaldi sold 14,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total transaction of $537,740.00. Following the completion of the sale, the senior vice president now directly owns 28,232 shares of the company’s stock, valued at approximately $1,084,391.12. The disclosure for this sale can be found here. In the last three months, insiders sold 117,915 shares of company stock valued at $4,160,901. 3.90% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA increased its holdings in Acceleron Pharma by 969.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 3,288 shares in the last quarter. NJ State Employees Deferred Compensation Plan purchased a new stake in Acceleron Pharma in the 2nd quarter worth $213,000. Bank of Montreal Can purchased a new stake in Acceleron Pharma in the 1st quarter worth $237,000. Parametric Portfolio Associates LLC purchased a new stake in Acceleron Pharma in the 1st quarter worth $241,000. Finally, Tudor Investment Corp ET AL increased its holdings in Acceleron Pharma by 8.5% in the 1st quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 716 shares in the last quarter. 88.07% of the stock is owned by institutional investors.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.